Compare EQNR & BSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EQNR | BSX |
|---|---|---|
| Founded | 1972 | 1979 |
| Country | Norway | United States |
| Employees | 24140 | N/A |
| Industry | Integrated oil Companies | Medical/Dental Instruments |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 96.0B | 93.4B |
| IPO Year | N/A | 2010 |
| Metric | EQNR | BSX |
|---|---|---|
| Price | $39.63 | $55.97 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 22 |
| Target Price | $37.00 | ★ $93.18 |
| AVG Volume (30 Days) | 3.8M | ★ 18.3M |
| Earning Date | 05-06-2026 | 04-22-2026 |
| Dividend Yield | ★ 3.08% | N/A |
| EPS Growth | N/A | ★ 55.20 |
| EPS | N/A | ★ 0.90 |
| Revenue | N/A | ★ $9,076,000,000.00 |
| Revenue This Year | $13.35 | $11.85 |
| Revenue Next Year | N/A | $10.16 |
| P/E Ratio | ★ $14.56 | $58.68 |
| Revenue Growth | N/A | ★ 12.49 |
| 52 Week Low | $22.26 | $52.52 |
| 52 Week High | $43.46 | $109.50 |
| Indicator | EQNR | BSX |
|---|---|---|
| Relative Strength Index (RSI) | 54.89 | 42.84 |
| Support Level | $23.15 | N/A |
| Resistance Level | $41.88 | $58.18 |
| Average True Range (ATR) | 1.00 | 1.60 |
| MACD | -0.02 | 0.13 |
| Stochastic Oscillator | 63.18 | 60.95 |
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2025 (50% liquids) and ended 2025 with 5.2 billion barrels of proven reserves (45% liquids). Operations also include oil refineries and natural gas processing, marketing, and trading. The renewables portfolio includes offshore and onshore wind and solar, with total power generation of 5.65 TWh in 2025.
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.